Cost-effectiveness results from the health system perspective for novel tuberculosis vaccines by country and vaccine.
- Allison Portnoy (7533053)
- Rebecca A. Clark (14498405)
- Matthew Quaife (7038788)
- Chathika K. Weerasuriya (14498408)
- Christinah Mukandavire (14498411)
- Roel Bakker (213033)
- Arminder K. Deol (10873265)
- Shelly Malhotra (777091)
- Nebiat Gebreselassie (5447510)
- Matteo Zignol (94959)
- So Yoon Sim (14498414)
- Raymond C. W. Hutubessy (4503268)
- Inés Garcia Baena (14498417)
- Nobuyuki Nishikiori (62361)
- Mark Jit (43662)
- Richard G. White (92065)
- Nicolas A. Menzies (8677533)
Publication date
January 2023
DOI Publisher
Public Library of Science (PLoS)Abstract
Note: Points represent each of 105 LMICs analyzed in the base-case scenario, stratified by TB incidence per 100,000. Line represents a cost-effectiveness threshold of 1× per-capita GDP in 2020. Vaccine introduction would be considered cost-effective for countries falling underneath this line. DALY, disability-adjusted life year; GDP, gross domestic product; LMIC, low- and middle-income country; TB, tuberculosis.</p
Add to ORKG